Sprout Pharmaceuticals, Inc.

A social media post by Sprout Pharmaceuticals ’ founder and CEO for the hypoactive sexual desire disorder drug Addyi (flibanserin) failed to include risk information, the US Food and Drug Administrat

The US Food and Drug Administration is starting to post information to key drug databases on its website again after most of its public communications were halted 21 January. The Center for Drug Evalu

A drug company’s risk of receiving a promotion enforcement letter from the US Food and Drug Administration may increase with corporate mergers and acquisitions and a failure to clear away old advertis

The US Food and Drug Administration’s imminent action on Biogen Pharma and Eisai Co., Ltd. ’s Alzheimer’s drug aducanumab is bound to be controversial, regardless of whether the agency approves the